A cross-Sectional Study in Iraq of 145 Patients with Medullary Psoriasis

Abstract

Background: Psoriasis is expressed as a chronic, non-contagious inflammatory skin illness that can disrupt social connections. Patients with psoriasis may experience stigma, which can lead to psychological illnesses such as anxiety and sadness. Objective: This paper was aimed to analyse the outcomes of medullary psoriasis for 145 Iraqi patients. Patients and methods: This study acquired the databases of psoriasis patients to analyse of a cross-sectional study in Iraq of 145 patients with medullary psoriasis.  The databases were analysed and designed by the SPSS program. The study grouped 145 psoriasis patients from different hospitals in Iraq who underwent a cross-sectional analysis. The methodology included two groups, with 70 patients receiving phototherapy and 75 patients using tazarotene cream, respectively. As part of this study conducted between 14th May 2021 to 26th August 2022, we presented the clinical features and demographic characteristics of medullary psoriasis in people under 40 years of age of all sexes. Discussion: In similarly with the last studies, it found (64) 44.1% for BMI of normal weight. Also, our outcomes found that females (74) 51% have had psoriasis more than males (71) 49%. In this study, 10.34% of patients reported psoriatic arthritis, and 15.86% of patients had Dry skin, with more than a quarter of patients having burning 20.69% and Itching with13.79; also, Nail affection was the lesser effect of psoriatic arthritis with 11.72%. As well as, our results complications showed that patients by tazarotene cream treatment got 45 of 75 cases while patients by phototherapy treatment had 26 of 70 cases. Conclusion: Our study found that phototherapy treatment got less percentage of complications for psoriatic patients in comparison with tazarotene cream. Our study confirmed that phototherapy is the best treatment of psoriasis patients in comparison with tazarotene cream treatment

Keywords

Medullary psoriasis; Tazarotene cream; and Phototherapy